Cognizant Technology Solutions
CTSH
$62.31
-3.60%
Cognizant Technology Solutions is a multinational IT services provider offering consulting, digital transformation, and business process outsourcing to enterprise clients across financial services, healthcare, and resources. As a major player in the global IT services industry, Cognizant differentiates itself through its global delivery model, leveraging a large offshore workforce in India to provide cost-effective solutions. The current investor narrative centers on the company's recovery from a challenging period marked by a significant stock decline, with recent quarterly results showing improved revenue growth and a strategic focus on AI-driven services. Attention is also on management's ability to navigate macroeconomic headwinds and competitive pressures while restoring investor confidence.…
CTSH
Cognizant Technology Solutions
$62.31
Related headlines
Investment Opinion: Should I buy CTSH Today?
Rating: Hold. The consensus is a 'buy' with an average target of $63.94, but the current price is essentially at that level, offering minimal upside. The thesis is that Cognizant is a stable, undervalued IT services provider with improving growth, but the market is not yet convinced of a sustained turnaround.
Sign up to view all
CTSH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Cognizant's valuation is attractive, but the stock's underperformance and high PEG ratio temper enthusiasm. The key is whether the growth acceleration is sustainable. If revenue growth exceeds 6% and margins expand, the stance would upgrade to bullish. Conversely, a slowdown would reinforce bearish sentiment.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cognizant Technology Solutions's 12-month outlook, with a consensus price target around $64.18 and implied upside of +3.0% versus the current price.
Average Target
$64.18
0 analysts
Implied Upside
+3.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$42 - $84
Analyst target range
Analyst coverage is robust with 25 analysts, and the consensus recommendation is a 'buy' with a mean rating of 2.21 (where 1 is strong buy and 5 is sell). The average target price is $63.94, which is essentially in line with the current price of $64.04, implying a negligible 0.2% downside. The distribution includes 10 buy ratings, 12 hold, and 3 sell, reflecting a cautiously optimistic stance. The low target of $42.00 suggests a bearish scenario, while the high target of $84.00 implies a 31% upside, indicating significant divergence in analyst expectations. Recent ratings actions have been mixed, with Wedbush upgrading to Outperform in June, while Citigroup and Baird maintained Neutral, suggesting no clear directional shift.
Drowning in data?
Find the real signal!
Bulls vs Bears: CTSH Investment Factors
Cognizant shows signs of a turnaround with accelerating revenue growth and improved profitability, but the stock has lagged the market significantly. The forward PE suggests undervaluation relative to peers, yet the high PEG ratio and mixed analyst targets introduce uncertainty. The bull case rests on sustained growth and margin expansion, while the bear case hinges on macro headwinds and competitive pressures. Currently, the evidence slightly favors the bull case due to improving fundamentals and a reasonable valuation, but the key tension is whether the recent growth acceleration is sustainable in a challenging macro environment.
Bullish
- Revenue growth accelerating: Q1 2026 revenue grew 5.83% YoY to $5.413B, up from 2.5% growth in Q1 2025, indicating a rebound in demand. Sequential growth from Q4 2025 ($5.333B) further confirms momentum.
- Strong profitability metrics: Operating margin improved to 16.7% in Q1 2026 from 15.6% in Q4 2025, and net margin rose to 12.2%. EBITDA margin held steady at 18.8%, showing operational efficiency.
- Attractive forward valuation: Forward PE of 10.14x is significantly below the trailing PE of 18.2x, implying the market expects strong earnings growth. This is a 27% discount to the industry average PE of 25x.
- Healthy balance sheet: Debt-to-equity is only 0.105, and current ratio is 2.34, indicating low financial risk. This provides flexibility for investments and buybacks.
Bearish
- Stock underperformed market: CTSH is down 10.71% over the past year, while the S&P 500 gained 18.56%. Relative strength is -29.27% over 1 year, indicating persistent underperformance.
- High PEG ratio signals overvaluation: PEG ratio of 20.57x suggests that the market is pricing in very high growth expectations, which may not be sustainable. This could lead to multiple compression if growth disappoints.
- Revenue concentration risk: Financial Services and Healthcare segments contribute 60% of revenue, making the company vulnerable to sector-specific downturns. Products and Resources segment is smaller and may be a drag.
- Mixed analyst targets: While the average target is $63.94, the low target is $42, implying a 34% downside. The wide range (42-84) reflects uncertainty about the company's growth trajectory.
CTSH Technical Analysis
Cognizant's stock has experienced a volatile year, with a 1-year price change of -10.71%, reflecting a broader downtrend despite a recent recovery. The current price of $64.04 sits at 73.5% of the 52-week range (low $37.08, high $87.03), indicating a rebound from the lows but still well below the highs. This positioning suggests the stock is in a recovery phase, having climbed from its June 2026 trough, but remains under pressure from the longer-term bearish trend.
Beta
0.83
0.83x market volatility
Max Drawdown
-55.3%
Largest decline past year
52-Week Range
$37-$87
Price range past year
Annual Return
-12.8%
Cumulative gain past year
| Period | CTSH Return | S&P 500 |
|---|---|---|
| 1m | +11.7% | +0.1% |
| 3m | +17.1% | +4.4% |
| 6m | -6.0% | +14.6% |
| 1y | -12.8% | +18.6% |
| ytd | -23.3% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTSH Fundamental Analysis
Cognizant's revenue has shown a positive trajectory, with Q1 2026 revenue of $5.413 billion, up 5.83% year-over-year, and sequential growth from $5.333 billion in Q4 2025. This marks an acceleration from the 2.5% growth in Q1 2025, indicating a rebound in demand. The growth is broad-based, with Financial Services contributing $1.644 billion and Healthcare $1.579 billion, while Products and Resources added $1.321 billion, though the latter may be a drag given its smaller size. The company's ability to sustain this growth will be critical, as the IT services industry faces pricing pressure and competition from peers.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
29.6%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTSH Overvalued?
Given Cognizant's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 18.20x, while the forward PE is 10.14x, implying the market expects significant earnings growth, with a PEG ratio of 20.57x suggesting that growth is priced in. Compared to the industry average PE of 25x (from valuation data), Cognizant trades at a 27% discount, which may reflect its lower growth prospects relative to peers. Historically, the stock's PE has ranged from 11x to 21x over the past year, with the current 18.2x near the higher end, indicating the market is pricing in a recovery, but not at extreme levels.
PE
18.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are moderate: debt-to-equity is low at 0.105, and the current ratio of 2.34 indicates strong liquidity. However, the company's reliance on continued growth is evident from the forward PE of 10.14x, which implies aggressive earnings expectations. If growth decelerates, the stock could face multiple compression. Additionally, the payout ratio of 27.35% suggests a modest dividend, but any cut would signal distress.